Nicotinic and opioid receptor interactions in nicotine addiction

Molecular Interventions

Volumn 6, Issue 6, 2006, Pages 311-314

  McGehee, Daniel S ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINE; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; DOPAMINE; MU OPIATE RECEPTOR; NALOXONE; NICOTINE; NICOTINIC RECEPTOR; NICOTINIC RECEPTOR BLOCKING AGENT; OPIATE RECEPTOR;

BEHAVIOR; BRAIN NERVE CELL; BRAIN REGION; DOPAMINE RELEASE; DOPAMINERGIC TRANSMISSION; DRUG EFFECT; GABAERGIC SYSTEM; HUMAN; NONHUMAN; PROTEIN EXPRESSION; REVIEW; TOBACCO DEPENDENCE; UPREGULATION;

ANIMALS; DOPAMINE; HUMANS; MICE; NEURONS; NICOTINIC AGONISTS; PROTEIN SUBUNITS; RECEPTOR CROSS-TALK; RECEPTORS, NICOTINIC; RECEPTORS, OPIOID; TOBACCO USE DISORDER; VENTRAL TEGMENTAL AREA;

EID: 33845980618     PISSN: 15340384     EISSN: 15432548     Source Type: Journal    
DOI: 10.1124/mi.6.6.4     Document Type: Review

References (51)

1. Nestler, E.J. Molecular basis of long-term plasticity underlying addiction. Nat. Rev. Neurosci. 2, 119-128 (2001).
2. Nestler, E.J. and Aghajanian, G.K. Molecular and cellular basis of addiction. Science 278, 58-63 (1997).
3. Koob, G.F. and Le Moal, M. Drug abuse: Hedonic homeostatic dysregulation. Science 278, 52-58 (1997).
4. Wise, R.A. Neurobiology of addiction. Curr. Opin. Neurobiol. 6, 243-251 (1996).
5. McGehee, D. and Role, L. Physiological diversity of nicotinic acetylcholine receptors expressed by vertebrate neurons. Annu. Rev. Physiol. 57, 521-546 (1995).
6. Sargent, P.B. The diversity of neuronal nicotinic acetylcholine receptors. Annu. Rev. Neurosci. 16, 403-443 (1993).
7. Champtiaux, N., Gotti, C., Cordero-Erausquin, M. et al. Subunit composition of functional nicotinic receptors in dopaminergic neurons investigated with knock-out mice. Journal of Neuroscience 23, 7820-7829 (2003). This study used genetically modified mice to investigate the nAChR subtypes expressed by VTA dopamine neurons.
8. Klink, R., de Kerchove d'Exaerde, A., Zoli, M., and Changeux, J.P. Molecular and physiological diversity of nicotinic acetylcholine receptors in the midbrain dopaminergic nuclei. J. Neurosci. 21, 1452-1463 (2001). This study used genetically modified mice to investigate the nAChR subtypes expressed by VTA dopamine neurons.
9. Dani, J.A. Roles of dopamine signaling in nicotine addiction. Mol. Psychiatry 8, 255-256 (2003).
10. Tapper, A.R., McKinney, S.L., Nashmi, R. et al. Nicotine activation of alpha4* receptors: Sufficient for reward, tolerance, and sensitization. Science 306, 1029-1032 (2004). In this study, the authors replaced the alpha4 nAChR subunit gene with a mutant form that has 50-fold higher sensitivity to nicotine. The result was a mouse line that responded to 50-fold lower nicotine concentrations in behavioral, physiological, and biochemical assays, supporting a key role of this receptor in the behavioral effects of nicotine.
11. Fagen, Z.M., Mansvelder, H.D., Keath, J.R., and McGehee, D.S. Shortand long-term modulation of synaptic inputs to brain reward areas by nicotine. Ann. N.Y. Acad. Sci. 1003, 185-95 (2003).
12. Mansvelder, H.D. and McGehee, D.S. Cellular and synaptic mechanisms of nicotine addiction. J. Neurobiol. 53, 606-617 (2002).
13. Picciotto, M.R., Zoli, M., Rimondini, R., Lena, C., Marubio, L.M., Pich, E.M., Fuxe, K., and Changeux, J.P. Acetylcholine receptors containing the beta2 subunit are involved in the reinforcing properties of nicotine. Nature 391, 173-177 (1998).
14. Pidoplichko, V.I., DeBiasi, M., Williams, J.T., and Dani, J.A. Nicotine activates and desensitizes midbrain dopamine neurons. Nature 390, 401-404 (1997).
15. Mansvelder, H.D. and McGehee, D.S. Long-term potentiation of excitatory inputs to brain reward areas by nicotine. Neuron 27, 349-357 (2000). This study was the first to demonstrate that a drug of abuse can induce LTP of the excitatory inputs to VTA dopamine neurons. Using a brain slice preparation, the authors showed that physiologically relevant nicotine concentrations enhanced excitatory drive to VTA dopamine neurons via presynaptic nAChRs, and activation of these receptors could replace presynaptic stimulation in LTP induction.
16. Mansvelder, H.D., Keath, J.R., and McGehee, D.S. Synaptic mechanisms underlie nicotine-induced excitability of brain reward areas. Neuron 33, 905-919 (2002). This study explored nAChR-mediated modulation of GABA transmission in the VTA, showing enhancement followed by inhibition of GABAergic inputs to dopamine neurons. Inhibiting the GABAergic inputs leads to a disinhibition of the dopamine neurons, which arises from the desensitization of the high-affinity nAChRs expressed on the GABA neurons.
17. Alkondon, M. and Albuquerque, E.X. Nicotinic receptor subtypes in rat hippocampal slices are differentially sensitive to desensitization and early in vivo functional up-regulation by nicotine and to block by bupropion. J. Pharmacol. Exp. Ther. 313, 740-750 (2005).
18. Buisson, B. and Bertrand, D. Chronic exposure to nicotine upregulates the human α4β2 nicotinic acetylcholine receptor function. J. Neurosci. 21, 1819-1829 (2001).
19. Kuryatov, A., Luo, J., Cooper, J., and Lindstrom, J. Nicotine acts as a pharmacological chaperone to up-regulate human α4β2 acetylcholine receptors. Mol. Pharmacol. 68, 1839-1851 (2005).
20. Vallejo, Y.F., Buisson, B., Bertrand, D., and Green, W.N. Chronic nicotine exposure upregulates nicotinic receptors by a novel mechanism. J. Neurosci. 25, 5563-5572 (2005).
21. Williams, J.T., Christie, M.J., and Manzoni, O. Cellular and synaptic adaptations mediating opioid dependence. Physiol. Rev. 81, 299-343 (2001).
22. Ford, C.P., Mark, G.P., and Williams, J.T. Properties and opioid inhibition of mesolimbic dopamine neurons vary according to target location. J. Neurosci. 26, 2788-2797 (2006). This study used fluorescent labeling to identify VTA dopamine neuron subtypes based on their projection targets. The authors then demonstrated differences in physiology and opioid receptor sensitivity of these dopamine neuron subtypes.
23. Cragg, S.J., Nicholson, C., Kume-Kick, J., Tao, L., and Rice, M.E. Dopamine-mediated volume transmission in midbrain is regulated by distinct extracellular geometry and uptake. J. Neurophysiol. 85, 1761-1771 (2001).
24. Beckstead, M.J., Grandy, D.K., Wickman, K., and Williams, J.T. Vesicular dopamine release elicits an inhibitory postsynaptic current in midbrain dopamine neurons. Neuron 42, 939-946 (2004).
25. Ferrari, R., Le Novere, N., Picciotto, M.R., Changeux, J.P., and Zoli, M. Acute and long-term changes in the mesolimbic dopamine pathway after systemic or local single nicotine injections. Eur. J. Neurosci. 15, 1810-1818 (2002).
26. Hemby, S.E., Martin, T.J., Co, C., Dworkin, S.I., and Smith, J.E. The effects of intravenous heroin administration on extracellular nucleus accumbens dopamine concentrations as determined by in vivo microdialysis. J. Pharmacol. Exp. Ther. 273, 591-598 (1995).
27. Devine, D.P., Leone, P., Pocock, D., and Wise, R.A. Differential involvement of ventral tegmental mu, delta, and kappa opioid receptors in modulation of basal mesolimbic dopamine release: In vivo microdialysis studies J. Pharmacol. Exp. Ther. 266, 1236-1246 (1993).
28. Hirose, N., Murakawa, K., Takada, K., Oi, Y., Suzuki, T., Nagase, H., Cools, A.R., and Koshikawa, N. Interactions among mu- and delta-opioid receptors, especially putative delta1- and delta2-opioid receptors, promote dopamine release in the nucleus accumbens. Neuroscience 135, 213-225 (2005).
29. Erhardt, S., Schwieler, L., and Engberg, G. Excitatory and inhibitory responses of dopamine neurons in the ventral tegmental area to nicotine. Synapse 43, 227-237 (2002).
30. Kiyatkin, E.A. and Rebec, G.V. Impulse activity of ventral tegmental area neurons during heroin self-administration in rats. Neuroscience 102, 565-580 (2001).
31. Grenhoff, J., Aston-Jones, G. and Svensson, T.H. Nicotinic effects on the firing pattern of midbrain dopamine neurons. Acta Physiol. Scand. 128, 351-358 (1986).
32. Dourmap, N., Clero, E., and Costentin, J. Involvement of cholinergic neurons in the release of dopamine elicited by stimulation of mu-opioid receptors in striatum. Brain Research 749, 295-300 (1997).
33. Lapchak, P.A., Araujo, D.M., and Collier, B. Regulation of endogenous acetylcholine release from mammalian brain slices by opiate receptors: Hippocampus, striatum and cerebral cortex of guinea-pig and rat. Neuroscience 31, 313-325 (1989).
34. Rada, P.V., Mark, G.P., Taylor, K.M., and Hoebel, B.G. Morphine and naloxone, i.p. or locally, affect extracellular acetylcholine in the accumbens and prefrontal cortex. Pharmaco. Biochem. Behav. 53, 809-816 (1996).
35. Fiserova, M., Consolo, S., and Krsiak, M. Chronic morphine induces long-lasting changes in acetylcholine release in rat nucleus accumbens core and shell: An in vivo microdialysis study. Psychopharmacology 142, 85-94 (1999).
36. Grady, S.R. et al. Characterization of nicotinic agonist-induced [3H]-dopamine release from synaptosomes prepared from four mouse brain regions. J. Pharmacol. Exp. Ther. 301, 651-660 (2002).
37. Rice, M.E. and Cragg, S.J. Nicotine amplifies reward-related dopamine signals in striatum. Nat. Neurosci. 7, 583-584 (2004). This study, along with reference 39, demonstrated that nicotine alters the frequency-dependence of dopamine release in the NAcc by desenstizing nAChRs on the dopamine terminals.
38. Zhou, F.M., Liang, Y., and Dani, J.A. Endogenous nicotinic cholinergic activity regulates dopamine release in the striatum. Nat. Neurosci. 4, 1224-1229 (2001).
39. Zhang, H. and Sulzer, D. Frequency-dependent modulation of dopamine release by nicotine. Nat. Neurosci. 7, 581-2 (2004). This study, along with reference 37, demonstrated that nicotine alters the frequency-dependence of dopamine release in the NAcc by desenstizing nAChRs on the dopamine terminals.
40. Svingos, A.L., Chavkin, C., Colago, E.E., and Pickel, V.M. Major coexpression of kappa-opioid receptors and the dopamine transporter in nucleus accumbens axonal profiles. Synapse 42, 185-192 (2001).
41. Davenport, K.E., Houdi, A.A., and Van Loon, G.R. Nicotine protects against mu-opioid receptor antagonism by beta-funaltrexamine: Evidence for nicotine-induced release of endogenous opioids in brain. Neurosci. Lett. 113, 40-46 (1990).
42. Dhatt, R.K., Gudehithlu, K.P., Wemlinger, T.A., Tejwani, G.A., Neff, N.H., and Hadjiconstantinou, M. Preproenkephalin mRNA and methionineenkephalin content are increased in mouse striatum after treatment with nicotine. J Neurochem 64, 1878-83 (1995). This is one of the first studies implicating a link between nicotine and the opioid system, showing an increase in endogenous opioid expression.
43. Wewers, M.E., Dhatt, R.K., Snively, T.A., and Tejwani, G.A. The effect of chronic administration of nicotine on antinociception, opioid receptor binding and met-enkelphalin levels in rats. Brain Res. 822, 107-113 (1999).
44. Walters, C.L., Cleck, J.N., Kuo, Y.C., and Blendy, J.A. Mu-opioid receptor and CREB activation are required for nicotine reward. Neuron 46, 933-943 (2005). This study used transgenic animals to demonstrate a link between MOR activity and the reinforcing effects of nicotine, which was also shown to be dependent upon activation of the transcription factor CREB.
45. Corrigall, W.A., Herling, S., and Coen, K.M. Evidence for opioid mechanisms in the behavioral effects of nicotine. Psychopharmacology (Berl) 96, 29-35 (1988).
46. Berrendero, F. and Maldonado, R. Involvement of the opioid system in the anxiolytic-like effects induced by Delta(9)-tetrahydrocannabinol. Psychopharmacology (Berl) 163, 111-117 (2002).
47. Richter, K.P., Gibson, C.A., Ahluwalia, J.S. and Schmelzle, K.H. Tobacco use and quit attempts among methadone maintenance clients. Am. J. Public Health 91, 296-299 (2001).
48. Clemmey, P., Brooner, R., Chutuape, M.A., Kidorf, M., and Stitzer, M. Smoking habits and attitudes in a methadone maintenance treatment population. Drug Alcohol Depend. 44, 123-132 (1997).
49. Lerman, C., Wileyto, E.P., Patterson, F. et al. The functional mu opioid receptor (OPRM1) Asn40Asp variant predicts short-term response to nicotine replacement therapy in a clinical trial. Pharmacogenomics J. 4, 184-192 (2004). Following up on preclinical studies from Blendy et al., this investigation of a human variant in the MOR gene demonstrated a higher likelihood of success with smoking cessation treatment in those individuals with the mutation.
50. Ray, R., Jepson, C., Patterson, F. et al. Association of OPRM1 A118G variant with the relative reinforcing value of nicotine. Psychopharmacology (Berl) 188, 355-363 (2006).
51. Caggiula, A.R., Donny, E.C., White, A.R., Chaudhri, N., Booth, S., Gharib, M.A., Hoffman, A., Perkins, K.A., and Sved, A.F. Environmental stimuli promote the acquisition of nicotine self-administration in rats. Psychopharmacology (Berl) 163, 230-237 (2002).